Skip to content
10-K

Annual Report

MEDITE CANCER DIAGNOSTICS, INC.

0001654954-18-005606

← back to feed
Filed
May 17, 2018 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2017 · May 17, 2018 56.66M sh
Operating Cash Flow FY 2017 · Dec 31, 2017 −$3.57M
Operating Cash Flow FY 2017 · Dec 31, 2016 −$1.09M
Long Term Debt FY 2017 · Dec 31, 2017 $4.87M
Long Term Debt FY 2017 · Dec 31, 2016 $60K
Short Term Debt FY 2017 · Dec 31, 2017 −$50K
Short Term Debt FY 2017 · Dec 31, 2016 −$3.21M
Cash And Equivalents FY 2017 · Dec 31, 2017 $73K
Cash And Equivalents FY 2017 · Dec 31, 2016 $108K
Cash And Equivalents FY 2017 · Dec 31, 2015 $587K
Stockholders Equity FY 2017 · Dec 31, 2017 $5.78M
Stockholders Equity FY 2017 · Dec 31, 2016 $8.02M
Stockholders Equity FY 2017 · Dec 31, 2015 $9.17M
Current Liabilities FY 2017 · Dec 31, 2017 $3.78M
Current Liabilities FY 2017 · Dec 31, 2016 $7.35M
Total Liabilities FY 2017 · Dec 31, 2017 $10.18M
Total Liabilities restated FY 2017 · Dec 31, 2016 $9.55M
Current Assets FY 2017 · Dec 31, 2017 $3.46M
Current Assets FY 2017 · Dec 31, 2016 $5.34M
Total Assets FY 2017 · Dec 31, 2017 $15.96M
Total Assets restated FY 2017 · Dec 31, 2016 $17.57M
Rd Expense FY 2017 · Dec 31, 2017 $1.19M
Rd Expense FY 2017 · Dec 31, 2016 $1.48M
Net Income FY 2017 · Dec 31, 2017 −$6.81M
Net Income FY 2017 · Dec 31, 2016 −$2.16M
Operating Income FY 2017 · Dec 31, 2017 −$6.48M
Operating Income FY 2017 · Dec 31, 2016 −$1.66M
Gross Profit FY 2017 · Dec 31, 2017 $162K
Gross Profit FY 2017 · Dec 31, 2016 $3.63M
Cost Of Revenue FY 2017 · Dec 31, 2017 $6.65M
Cost Of Revenue FY 2017 · Dec 31, 2016 $5.61M
Revenue FY 2017 · Dec 31, 2017 $6.81M
Revenue FY 2017 · Dec 31, 2016 $9.24M